Suven Life Sciences informs about press release

16 Aug 2021 Evaluate

Suven Life Sciences has informed that it enclosed News Release of the company titled 'Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer's type dementias'. In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended and in terms of the Code of Conduct of the Company for prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall remain closed for the Directors, Promoters, other Designated Persons, and immediate relatives of Designated Persons covered under the said code read with the SEBI Regulations, from 17th August 2021 to 18th August 2021. Trading window will be opened from 19th August, 2021.

The above information is a part of company’s filings submitted to BSE.

Suven Life Sciences Share Price

166.05 -1.75 (-1.04%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×